MYK-461 clinical trials
Also written Mavacamten, MYK-461 and BMS-986427.
Its developmentBy Bristol-Myers Squibb and LianBio, step by step21 company-led studies, furthest phase 4: when each phase was reached, its deals, target and what is ahead.How each study uses MYK-461 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the MYK-461 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 28 Apr 2022 · CAMZYOS · NDA 214998 (FDA, Drugs@FDA)
- European Union
- 26 Jun 2023 · Camzyos · EMEA/H/C/005457 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
25 studies that test it; most in 2022 (5)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2018 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 2 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 21 · Other 4
Bristol-Myers Squibb (13) · MyoKardia, Inc. (6) · LianBio LLC (2) · Xu Liu (1) · Second Affiliated Hospital, Zhejiang University, School of Medicine (1) · Second Affiliated Hospital of Nanchang University (1) · University of Manchester (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test MYK-461.
- Nov 2026The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular ObstructionPhase 4 · Second Affiliated Hospital, Zhejiang University, School of Medicine
Studies
Open first, then newest update. How each study uses MYK-461 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 25
- A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)Not yet recruitingPhase 3Bristol-Myers SquibbNCT07940777Written as MavacamtenHow we know
- Efficacy and Safety of an LVEF-Guided Mavacamten Dose Up-Titration Strategy in Chinese Patients With Symptomatic Obstructive Hypertrophic CardiomyopathyNot yet recruitingPhase 4Second Affiliated Hospital of Nanchang UniversityNCT07807384Written as MavacamtenHow we know
- Positron Emission Tomography to Assess the Effect of Camzyos on Ischaemia in HOCM: PEACH TrialRecruitingNot applicableUniversity of ManchesterNCT07120776Written as Camzyos (Mavacamten)How we know
- The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular ObstructionEnrolling by invitationPhase 4Second Affiliated Hospital, Zhejiang University, School of MedicineNCT07103655Written as mavacamtenHow we know
- A Study of Mavacamten in Non-Obstructive Hypertrophic CardiomyopathyTerminatedPhase 3Bristol-Myers SquibbNCT05582395Written as MavacamtenHow we know
- A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruitingPhase 4Bristol-Myers SquibbNCT06112743Written as MavacamtenHow we know
- A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)Active, not recruitingPhase 4Bristol-Myers SquibbNCT07004972Written as MavacamtenHow we know
- A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMCompletedPhase 2/3Bristol-Myers SquibbNCT03723655Written as mavacamtenHow we know
- A Study of Mavacamten in Obstructive Hypertrophic CardiomyopathyCompletedPhase 3Bristol-Myers SquibbNCT05414175Written as MavacamtenHow we know
- A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyActive, not recruitingPhase 3Bristol-Myers SquibbNCT06253221Written as MavacamtenHow we know
- A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction TherapyCompletedPhase 3Bristol-Myers SquibbNCT04349072Written as MavacamtenHow we know
- Efficacy of Mavacamten in Patients With Symptomatic Latent Obstructive Hypertrophic CardiomyopathyActive, not recruitingNot applicableXu LiuNCT06947590Written as mavacamtenHow we know
- A Study of Mavacamten in Participants With HFpEF and Elevation of NT-proBNP With or Without Elevation of cTnTCompletedPhase 2Bristol-Myers SquibbNCT04766892Written as mavacamtenHow we know
- Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEERCompletedPhase 2Bristol-Myers SquibbNCT03496168Written as mavacamtenHow we know
- A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCMCompletedPhase 3LianBio LLCNCT05174416Written as MavacamtenHow we know
- Study Evaluating the Pharmacokinetics of Mavacamten in Healthy Adult Chinese SubjectsCompletedPhase 1LianBio LLCNCT05135871Written as MavacamtenHow we know
- A Study to Evaluate the Effects of Mavacamten in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05719805Written as MavacamtenHow we know
- A Study to Evaluate the Effects on the Single-Dose Drug Levels of Mavacamten in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05362045Written as MavacamtenHow we know
- A Study to Evaluate the Effect of Activated Charcoal With Sorbitol on the Single-dose of Mavacamten in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05320094Written as MavacamtenHow we know
- A Phase 2 Study of Mavacamten in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)CompletedPhase 2MyoKardia, Inc.NCT03442764Written as mavacamtenHow we know
See all 25 studies that test MYK-461 →
Given beside what is tested · 1 — MYK-461 is usual care or a partner of the new treatment
What changed recently
From the registry's own updates since Oct 21, 2026.
Newly registered1
Codes
What other systems call MYK-461 · ClinicalTrials.gg INT000419
- MeSH (NLM) C000605992MYK-461Confirmed ClinicalTrials.gov, NLM
- UNII (FDA) QX45B99R3JMAVACAMTENConfirmed FDA, NLM
- RxNorm 2600867One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605992 | MYK-461 | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | QX45B99R3J | MAVACAMTEN | Confirmed FDA, NLM |
| RxNorm | 2600867 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.